Manifestations and treatment of acute graft-versus-host disease

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1287-1303

  Cutler, Corey ^a   Antin, Joseph H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cytokine levels and gene polymorphisms; Grading and severity scores; Graft composition and hematopoietic stem cell dose; Lymphocyte depletion of transfused blood products; Manifestations and treatment of acute graft versus host disease; Supportive care; Transfusion associated GVHD

Indexed keywords

EID: 77953012692     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch86     Document Type: Chapter

References (337)

1. Barnes D LJ. Spleen protection: the cellular hypothesis. In: Bacq ZM, ed. Radiobiology Sympo-sium. London: Butterworth; 1955.
2. Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. Transplant Bull 1957; 4: 67-71.
3. Simonsen M. Graft-versus-host-reactions: the history that never was, and the way things happened to happen. Immunol Rev 1985; 88: 5-23.
4. Gatti RA, Kersey JH, Yunis EJ, Good RA. Graftversus- host disease. Prog Clin Pathol 1973; 5: 1-18.
5. Graw RG, Jr., Rogentine GN, Jr., Leventhal BG et al. Graft-versus-host reaction complicating HLA matched bone-marrow transplantation. Lancet 1970; 2: 1053-5.
6. Kersey JH, Meuwissen HJ, Good RA. Graft versus host reactions following transplantation of allogeneic hematopoietic cells. Hum Pathol 1971; 2: 389-402.
7. Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Haematopoietic Chimera In Man After Allogenic (Homologous) Bone-marrow Transplantation. (Control Of The Secondary Syndrome. Specific Tolerance Due To The Chimerism). Br Med J 1963; 2: 1633-5.
8. Grebe SC, Streilein JW. Graft-versus-Host reactions: a review. Adv Immunol 1976; 22: 119-221.
9. Hathaway WE, Githens JH, Blackburn WR, Fulginiti V, Kempe CH. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease. N Engl J Med 1965; 273: 953-8.
10. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leukemia and Lymphoma 2005; 46: 1251-60.
11. Billingham R. The biology of graft-versus-host reactions. The Harvey Lectures[62], 21-78. 1966. Academic Press.
12. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-8.
13. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev 2003; 17: 187-94.
14. Korngold R, Sprent J. T cell subsets and graftversus- host disease. Transplantation 1987; 44: 335-9.
15. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-74.
16. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 347-56.
17. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280-9.
18. van Bekkum DW, Roodenburg J, Heidt PJ, van der WD. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-4.
19. Storb R, Prentice RL, Buckner CD et al. Graftversus- host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302-7.
20. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267-75.
21. Trenschel R, Peceny R, Runde V et al. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination. Bone Marrow Transplant 2000; 26: 993-7.
22. Grundy JE, Shanley JD, Shearer GM. Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation 1985; 39: 548-53.
23. Cooke KR, Gerbitz A, Crawford JM et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-9.
24. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002; 8: 441-8.
25. Petersen FB, Buckner CD, Clift RA et al. Laminar air flow isolation and decontamination: a prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients. Infection 1986; 14: 115-21.
26. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668-76.
27. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: longterm follow-up of a randomized, placebocontrolled trial. Blood 2000; 96: 2055-61.
28. Krijanovski OI, Hill GR, Cooke KR et al. Keratinocyte growth factor separates graft-versusleukemia effects from graft-versus-host disease. Blood 1999; 94: 825-31.
29. Blazar BR, Weisdorf DJ, Defor T et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-22.
30. Atkinson K, Storb R, Weiden PL et al. In vitro tests correlating with presence or absence of graftvs- host disease in DLA nonidentical canine radiation chimeras: evidence that clonal abortion maintains stable graft-host tolerance. J Immunol 1980; 124: 1808-14.
31. Fukushi N, Arase H, Wang B et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci U S A 1990; 87: 6301-5.
32. Rosenkrantz K, Keever C, Bhimani K et al. Both ongoing suppression and clonal elimination contribute to graft-host tolerance after transplantation of HLA mismatched T cell-depleted marrow for severe combined immunodeficiency. J Immunol 1990; 144: 1721-8.
33. Trenado A, Sudres M, Tang Q et al. Ex vivoexpanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176: 1266-73.
34. Teshima T, Matsuoka K, Ichinohe T. Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) 2006; 54: 165-72.
35. Matsuoka K, Ichinohe T, Hashimoto D et al. Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+ CD25+ T-cell-dependent mechanism. Blood 2006; 107: 404-9.
36. Ichinohe T, Teshima T, Matsuoka K, Maruya E, Saji H. Fetal-maternal microchimerism: impact on hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 546-52.
37. van Rood JJ, Loberiza FR Jr., Zhang MJ et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99: 1572-7.
38. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-9.
39. Castro-Malaspina H, Harris RE, Gajewski J et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-51.
40. McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219-25.
41. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-72.
42. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-71.
43. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
44. Weisdorf D, Hakke R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-203.
45. Bross DS, Tutschka PJ, Farmer ER et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63: 1265-70.
46. Nash RA, Pepe MS, Storb R et al. Acute graftversus- host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
47. Beatty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249-53.
48. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-13.
49. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228-34.
50. Petersdorf EW, Kollman C, Hurley CK et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 2001; 98: 2922-9.
51. Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-30.
52. Ho VT, Kim HT, Liney D et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 845-50.
53. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-6.
54. Gallardo D, Brunet S, Torres A et al. Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graftversus- host disease. Transplantation 2004; 77: 1107-10.
55. Shaw BE, Potter MN, Mayor NP et al. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1001-8.
56. den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host diseaseassociated human minor histocompatibility antigen. Science 1995; 268: 1476-80.
57. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-5.
58. Martin PJ. How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation?. Bone Marrow Transplant 1997; 20: 97-100.
59. Morishima Y, Kodera Y, Hirabayashi N et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DRcompatible unrelated donors among Japanese. Bone Marrow Transplant 1995; 15: 235-9.
60. Klingemann HG, Deeg HJ, Self S, Thomas ED, Storb R. Is race a risk factor for allogeneic marrow transplantation?. Bone Marrow Transplant 1986; 1: 87-94.
61. Easaw SJ, Lake DE, Beer M et al. Graft-versushost disease. Possible higher risk for African American patients. Cancer 1996; 78: 1492-7.
62. Walters MC, Patience M, Leisenring W et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335: 369-76.
63. Balduini CL, Noris P, Giorgiani G et al. Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. Br J Haematol 1999; 106: 723-9.
64. Vogt MH, van den Muijsenberg JW, Goulmy E et al. The DBY gene codes for an HLA-DQ5- restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-32.
65. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-8.
66. Flowers ME, Pepe MS, Longton G et al. Previous donor pregnancy as a risk factor for acute graftversus- host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol 1990; 74: 492-6.
67. Kollman C, Howe CW, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-51.
68. Weisdorf D, Hakke R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-203.
69. Nash RA, Pepe MS, Storb R et al. Acute graftversus- host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
70. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-8.
71. Eiz-Vesper B, Seltsam A, Blasczyk R. ABO glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 960-8.
72. Seebach JD, Stussi G, Passweg JR et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11: 1006-13.
73. Klumpp TR, Herman JH, Ulicny J et al. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 615-20.
74. Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donordirected hemagglutinin titers after ABOmismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000; 96: 1150-6.
75. Rozman P, Kosir A, Bohinjec M. Is the ABO incompatibility a risk factor in bone marrow transplantation?. Transpl Immunol 2005; 14: 159-69.
76. Stussi G, Muntwyler J, Passweg JR et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 87-93.
77. Thomas E, Lochte H Jr., Lu W, Ferrebee J. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-6.
78. Pasquini M. Current Use and Outcome of Hematopoietic Stem Cell Transplantation 2005. http:// www.cibmtr.org/services/summary_slides.html. 2006.
79. Cutler C, Antin JH. Stem Cell Sources: Peripheral Blood Stem Cells and Bone Marrow for Allogeneic Transplantation. In: Soiffer RJ, ed. Stem Cell Transplantation for Hematologic Malignancies. Totowa, New Jersey: Humana Press; 2004:337-356.
80. Bacigalupo A, Zikos P, Van Lint M-T et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: A single-center experience. Exper Hematol 1998; 26: 409-14.
81. Russell JA, Larratt L, Brown C et al. Allogeneic blood stem cells and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant 1999; 24: 1177-83.
82. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graftversus- host disease. Blood 1997; 90: 4705-9.
83. Üstün C, Arslan Ö, Beksaç M et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 1999; 5: 28-35.
84. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-81.
85. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus Lenograstimprimed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-46.
86. Couban S, Simpson DR, Barnett MJ et al. A randomized multicentre comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-31.
87. Heldal D, Tjonnfjord G, Brinch L et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129-36.
88. Mahmoud H, Fahmy O, Kamel A et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355-8.
89. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 335: 1231-7.
90. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-7.
91. Vigorito AC, Azevedo WM, Marques JFC et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-51.
92. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral- blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-91.
93. Stem Cell Trialists' Collaborative Group. Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials. Journal of Clinical Oncology 2005; 23: 5074-87.
94. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-45.
95. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455-64.
96. Eapen M. Peripheral blood stem cells versus bone marrow for ablative transplantation. Biol Blood Marrow Transplant. 2007; 13 Suppl 1: 76-77.
97. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-75.
98. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-85.
99. Singhal S, Powles R, Kulkarni S et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 501-5.
100. Mohty M, Bilger K, Jourdan E et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graftversus- host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 869-75.
101. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-7.
102. Ringden O, Barrett AJ, Zhang MJ et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121: 874-85.
103. Przepiorka D, Smith TL, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-70.
104. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726-33.
105. Baron F, Maris MB, Storer BE et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 822-8.
106. Korbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-8.
107. Cao TM, Wong RM, Sheehan K et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33: 279-85.
108. Mohty M, Bagattini S, Chabannon C et al. CD8+ T cell dose affects development of acute graft-vshost disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol 2004; 32: 1097-102.
109. Cao TM, Shizuru JA, Wong RM et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005; 105: 2300-6.
110. Soiffer RJ, Alyea EP, Hochberg E et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625-32.
111. Jones SC, Murphy GF, Korngold R. Posthematopoietic cell transplantation control of graftversus- host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003; 9: 243-56.
112. Pabst C, Schirutschke H, Ehninger G, Bornhauser M, Platzbecker U. The Graft Content of Donor T Cells Expressing {gamma}{delta}TCR+ and CD4+foxp3+ Predicts the Risk of Acute Graft versus Host Disease after Transplantation of Allogeneic Peripheral Blood Stem Cells from Unrelated Donors. Clin Cancer Res 2007; 13: 2916-22.
113. Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-7.
114. Wolf D, Wolf AM, Fong D et al. Regulatory T-cells in the graft and the risk of acute graftversus- host disease after allogeneic stem cell transplantation. Transplantation 2007; 83: 1107-13.
115. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2007; 85: 154-62.
116. Stanzani M, Martins SL, Saliba RM et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versushost disease after HLA-identical stem cell transplantation in humans. Blood 2004; 103: 1140-6.
117. Cavet J, Middleton PG, Segall M et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941-6.
118. Cavet J, Dickinson AM, Norden J et al. Interferon- gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001; 98: 1594-600.
119. Cullup H, Dickinson AM, Jackson GH et al. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001; 113: 807-13.
120. Hattori H, Matsuzaki A, Suminoe A et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graftversus- host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplant 2002; 30: 665-71.
121. Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graftversus- host disease. Hum Immunol 2005; 66: 700-10.
122. Lin MT, Storer B, Martin PJ et al. Relation of an interleukin-10 promoter polymorphism to graftversus- host disease and survival after hematopoietic- cell transplantation. N Engl J Med 2003; 349: 2201-10.
123. Lin MT, Storer B, Martin PJ et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 2005; 106: 3995-4001.
124. MacMillan ML, Radloff GA, Kiffmeyer WR et al. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation 2003; 76: 1758-62.
125. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998; 92: 3943-8.
126. Mlynarczewska A, Wysoczanska B, Karabon L, Bogunia-Kubik K, Lange A. Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 339-44.
127. Nordlander A, Uzunel M, Mattsson J, Remberger M. The TNFd4 allele is correlated to moderateto- severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br J Haematol 2002; 119: 1133-6.
128. Stark GL, Dickinson AM, Jackson GH et al. Tumour necrosis factor receptor type II 196 M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graftversus- host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76: 1742-9.
129. Takahashi H, Furukawa T, Hashimoto S et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 1317-23.
130. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2005; 90: 425-6.
131. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of interleukin- 1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2003; 122: 778-87.
132. Kim DH, Lee NY, Sohn SK et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 2005; 79: 1615-22.
133. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2006; 132: 326-32.
134. Seo KW, Kim DH, Sohn SK et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1089-95.
135. Chen C, Huang SL. Killer cell inhibitory receptors involved in graft-versus-host disease and graft-versus-leukemia effect in allogeneic hematopoietic stem cell transplantation -review. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004; 12: 236-43.
136. Gagne K, Brizard G, Gueglio B et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-80.
137. Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105: 2594-600.
138. Igarashi T, Wynberg J, Srinivasan R et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004; 104: 170-7.
139. Schaffer M, Malmberg KJ, Ringden O, Ljunggren HG, Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78: 1081-5.
140. Kalayoglu-Besisik S, Caliskan Y, Sargin D, Gurses N, Ozbek U. Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation 2003; 76: 1775-7.
141. Robien K, Schubert MM, Bruemmer B et al. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268-75.
142. Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation 2005; 79: 815-20.
143. Holler E, Rogler G, Herfarth H et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104: 889-94.
144. Middleton PG, Cullup H, Dickinson AM et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 223-8.
145. Middleton PG, Norden J, Cullup H et al. Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplant 2003; 32: 41-7.
146. Rozman P, Karas M, Kosir A et al. Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?. Bone Marrow Transplant 2003; 31: 497-506.
147. Socie G, Loiseau P, Tamouza R et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001; 72: 699-706.
148. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 2004; 127: 479-90.
149. Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come?. Bone Marrow Transplant 2005; 35: 1-16.
150. Socie G, Loiseau P, Tamouza R et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001; 72: 699-706.
151. Perez-Simon JA, Diez-Campelo M, Martino R et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394-403.
152. Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-12.
153. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-71.
154. Hill RS, Petersen FB, Storb R et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-6.
155. Petz LD, Yam P, Wallace RB et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood 1987; 70: 1331-7.
156. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203-5.
157. Weston LE, Geczy AF, Farrell C. Donor helper T-cell frequencies as predictors of acute graftversus- host disease in bone marrow transplantation between HLA-identical siblings. Transplantation 1997; 64: 836-41.
158. Vogelsang GB, Hess AD, Berkman AW et al. An in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical bone marrow transplants. N Engl J Med 1985; 313: 645-50.
159. Sviland L, Dickinson AM, Carey PJ, Pearson AD, Proctor SJ. An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1990; 5: 105-9.
160. Bagot M, Mary JY, Heslan M et al. The mixed epidermal cell lymphocyte-reaction is the most predictive factor of acute graft-versus-host disease in bone marrow graft recipients. Br J Haematol 1988; 70: 403-9.
161. Sahin S, Akoglu TF, Gurbuz O et al. Reevaluation of skin-explant model in graftversus- host disease prediction. Clin Transplant 1995; 9: 370-4.
162. Dickinson AM, Cavet J, Cullup H et al. Predicting outcome in hematological stem cell transplantation. Arch Immunol Ther Exp (Warsz) 2002; 50: 371-8.
163. Przepiorka D, Smith TL, Folloder J et al. Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation. Blood 1999; 94: 1465-70.
164. Saurat JH. Cutaneous manifestations of graftversus- host disease. Int J Dermatol 1981; 20: 249-56.
165. Sale GE, Shulman HM, Gallucci BB, Thomas ED. Young rete ridge keratinocytes are preferred targets in cutaneous graft-versus-host disease. Am J Pathol 1985; 118: 278-87.
166. Roy J, Snover D, Weisdorf S et al. Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease. Transplantation 1991; 51: 642-6.
167. Weisdorf DJ, Snover DC, Haake R et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-9.
168. Melin-Aldana H, Thormann K, Duerst R, Kletzel M, Jacobsohn DA. Hepatitic pattern of graft versus host disease in children. Pediatr Blood Cancer 2007; 49: 727-30.
169. Mullighan CG, Bogdanos DP, Vergani D, Bardy PG. Cytochrome P450 1A2 is a target antigen in hepatitic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 703-5.
170. Ma SY, Au WY, Ng IO et al. Hepatitic graftversus- host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation 2004; 77: 1252-9.
171. Akpek G, Boitnott JK, Lee LA et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903-7.
172. Malik AH, Collins RH, Jr., Saboorian MH, Lee WM. Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis. Am J Gastroenterol 2001; 96: 588-90.
173. Saito T, Shinagawa K, Takenaka K et al. Ocular manifestation of acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2002; 75: 332-4.
174. Jack MK, Jack GM, Sale GE, Shulman HM, Sullivan KM. Ocular manifestations of graft-v-host disease. Arch Ophthalmol 1983; 101: 1080-4.
175. Jabs DA, Wingard J, Green WR et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 1989; 107: 1343-8.
176. Kim RY, Anderlini P, Naderi AA et al. Scleritis as the initial clinical manifestation of graft-versushost disease after allogeneic bone marrow transplantation. Am J Ophthalmol 2002; 133: 843-5.
177. Lockman LA, Sung JH, Krivit W. Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrow transplant recipients. Pediatr Neurol 1991; 7: 457-63.
178. Provenzale JM, Graham ML. Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings. AJNR Am J Neuroradiol 1996; 17: 1290-4.
179. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse Alveolar Hemorrhage and Infection- Associated Alveolar Hemorrhage following Hematopoietic Stem Cell Transplantation: Related and High-Risk Clinical Syndromes. Biology of Blood and Marrow Transplantation 2006; 12: 1038-46.
180. Cutler C, Henry N, Magee C et al. Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2005; 11: 551-7.
181. Holler E, Kolb HJ, Hiller E et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-24.
182. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989; 73: 1054-8.
183. Bruno B, Gooley T, Sullivan KM et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154-62.
184. Kim DH, Sohn SK, Jeon SB et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006; 37: 101-8.
185. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-8.
186. Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graftvs- host disease: results of decision analysis. Arch Dermatol 2006; 142: 175-82.
187. Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 1997; 21: 988-96.
188. Zhou Y, Barnett MJ, Rivers JK. Clinical signifi- cance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000; 136: 717-21.
189. Ferrara JL. Novel strategies for the treatment and diagnosis of graft-versus-host-disease. Best Pract Res Clin Haematol 2007; 20: 91-7.
190. Jordan WJ, Brookes PA, Szydlo RM et al. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood 2004; 103: 717-24.
191. Srinivasan R, Daniels J, Fusaro V et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34: 796-801.
192. Weissinger EM, Schiffer E, Hertenstein B et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007.
193. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
194. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8.
195. Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graftversus- host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-64.
196. Cahn JY, Klein JP, Lee SJ et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGMTC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106: 1495-500.
197. Atkinson K, Horowitz MM, Biggs JC et al. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplant 1988; 3: 5-10.
198. Weisdorf DJ, Hurd D, Carter S et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9: 512-8.
199. Leisenring WM, Martin PJ, Petersdorf EW et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-55.
200. Flowers ME, Traina F, Storer B et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant 2005; 35: 277-82.
201. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8.
202. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-26.
203. Bacigalupo A. Management of acute graft-versushost disease. Br J Haematol 2007; 137: 87-98.
204. Van Lint MT, Uderzo C, Locasciulli A et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-93.
205. Hings IM, Filipovich AH, Miller WJ et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 1993; 56: 577-80.
206. MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-94.
207. Cragg L, Blazar BR, Defor T et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 441-7.
208. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-30.
209. Dugan MJ, DeFor TE, Steinbuch M, Filipovich AH, Weisdorf DJ. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997; 75: 41-6.
210. Graziani F, Van Lint MT, Dominietto A et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 2002; 87: 973-8.
211. Hockenbery DM, Cruickshank S, Rodell TC et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisonesparing therapy for gastrointestinal graft-versushost disease. Blood 2007; 109: 4557-63.
212. Lee SJ, Zahrieh D, Agura E et al. Effect of upfront daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559-64.
213. Cahn JY, Bordigoni P, Tiberghien P et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995; 60: 939-42.
214. Martin PJ, Nelson BJ, Appelbaum FR et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88: 824-30.
215. Uberti JP, Ayash L, Ratanatharathorn V et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graftversus- host disease. Biol Blood Marrow Transplant 2005; 11: 680-7.
216. Hsu B, May R, Carrum G, Krance R, Przepiorka D. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001; 28: 945-50.
217. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821-8.
218. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-60.
219. Khoury H, Kashyap A, Adkins DR et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-64.
220. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graftversus- host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147-53.
221. MacMillan ML, Weisdorf DJ, Davies SM et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-6.
222. Knop S, Hebart H, Gscheidle H et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 831-7.
223. Gleixner B, Kolb HJ, Holler E et al. Treatment of aGVHD with OKT3: clinical outcome and sideeffects associated with release of TNF alpha. Bone Marrow Transplant 1991; 8: 93-8.
224. Martin PJ, Shulman HM, Schubach WH et al. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graftversus- host disease with a murine anti-T-cell antibody. Ann Intern Med 1984; 101: 310-5.
225. Knop S, Hebart H, Gratwohl A et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 2007; 21: 1830-3.
226. Carpenter PA, Lowder J, Johnston L et al. A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid- Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 2005; 11: 465-71.
227. van Oosterhout YVJM, van Emst L, Schattenberg AVMB et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 2000; 95: 3693-701.
228. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393-7.
229. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126: 1398-403.
230. Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989; 86: 10029-33.
231. Anasetti C, Martin PJ, Hansen JA et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graftversus- host disease. Transplantation 1990; 50: 49-54.
232. Cuthbert RJ, Phillips GL, Barnett MJ et al. Antiinterleukin- 2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992; 10: 451-5.
233. Herve P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of antiinterleukin- 2 receptor monoclonal antibody (BB10). Blood 1990; 75: 1017-23.
234. Pinana JL, Valcarcel D, Martino R et al. Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 2006; 12: 1135-41.
235. Bay JO, Dhedin N, Goerner M et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005; 80: 782-8.
236. Anasetti C, Hansen JA, Waldmann TA et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320-7.
237. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology 2001; 112: 820-3.
238. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graftversus- host disease. Blood 2000; 95: 83-9.
239. Massenkeil G, Rackwitz S, Genvresse I et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versushost disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899-903.
240. Schmidt-Hieber M, Fietz T, Knauf W et al. Effi- cacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versushost disease. Br J Haematol 2005; 130: 568-74.
241. Funke VA, de Medeiros CR, Setubal DC et al. Therapy for severe refractory acute graft-versushost disease with basiliximab, a selective interleukin- 2 receptor antagonist. Bone Marrow Transplant 2006; 37: 961-5.
242. Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224-6.
243. Shaughnessy PJ, Bachier C, Grimley M et al. Denileukin diftitox for the treatment of steroidresistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 2005; 11: 188-93.
244. Deeg HJ, Blazar BR, Bolwell BJ et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052-8.
245. MacMillan ML, Couriel D, Weisdorf DJ et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007; 109: 2657-62.
246. Busca A, Locatelli F, Lovisone E et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath- 1H. Biol Blood Marrow Transplant 2005; 11: 734-6.
247. Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant 2004; 34: 285-7.
248. Carella AM, Beltrami G, Scalzulli PR, Carella AM, Jr., Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft-versushost disease (aGVHD). Bone Marrow Transplant 2004; 33: 131-2.
249. Varadi G, Or R, Slavin S, Nagler A. In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. Am J Hematol 1996; 52: 236-7.
250. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 45-52.
251. Wolff D, Roessler V, Steiner B et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003-10.
252. Kennedy GA, Butler J, Western R et al. Combination antithymocyte globulin and soluble TNF[alpha] inhibitor (etanercept) +//- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006; 37: 1143-7.
253. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-8.
254. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versushost disease with infliximab, a chimeric human/ mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-9.
255. Jacobsohn DA, Hallick J, Anders V et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74: 119-24.
256. Yamane T, Yamamura R, Aoyama Y et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 2003; 44: 2095-7.
257. Patriarca F, Sperotto A, Damiani D et al. Infliximab treatment for steroid-refractory acute graftversus- host disease. Haematologica 2004; 89: 1352-9.
258. Couriel D, Saliba R, Hicks K et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-54.
259. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non- Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-76.
260. Bolanos-Meade J, Jacobsohn DA, Margolis J et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661-8.
261. Basara N, Blau WI, Romer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-5.
262. Basara N, Kiehl MG, Blau W et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 2001; 33: 2121-3.
263. Krejci M, Doubek M, Buchler T et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84: 681-5.
264. Takami A, Mochizuki K, Okumura H et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006; 83: 80-5.
265. Baudard M, Vincent A, Moreau P et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 30: 287-95.
266. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-48.
267. Baan CC, van der Mast BJ, Klepper M et al. Differential Effect of Calcineurin Inhibitors, Anti- CD25 Antibodies and Rapamycin on the Induction of FOXP3 in Human T Cells. Transplantation 2005; 80: 110-7.
268. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743-8.
269. Zeiser RS, Nguyen VH, Beilhack A et al. Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production. Blood. 2006;2006-01.
270. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-7.
271. Monti P, Mercalli A, Leone BE et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003; 75: 137-45.
272. Hackstein H, Taner T, Zahorchak AF et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-63.
273. Chiang PH, Wang L, Liang Y et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function. Transplant Proc 2002; 34: 1394-5.
274. Woltman AM, de Fijter JW, Kamerling SW et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174-80.
275. Woltman AM, van der Kooij SW, Coffer PJ et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 1439-45.
276. Benito AI, Furlong T, Martin PJ et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924-9.
277. Wetzig T, Sticherling M, Simon JC et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35: 515-9.
278. Wiesmann A, Weller A, Lischka G et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151-5.
279. Furlong T, Leisenring W, Storb R et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versushost disease. Biol Blood Marrow Transplant 2002; 8: 206-12.
280. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 7-12.
281. Biagi E, Di Biaso I, Leoni V et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+ CD62 L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31-9.
282. Greinix HT, Volc-Platzer B, Kalhs P et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426-31.
283. Richter HI, Stege H, Ruzicka T et al. Extracorporeal photopheresis in the treatment of acute graftversus- host disease. J Am Acad Dermatol 1997; 36: 787-9.
284. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versushost disease. Ther Apher 2002; 6: 296-304.
285. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-34.
286. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet 2004; 363: 1439-41.
287. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapyresistant graft-versus-host disease. Transplantation 2006; 81: 1390-7.
288. Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M. Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol 2006; 81: 959-62.
289. Sato T, Sakamaki S, Nagaoka Y et al. Intramesenteric artery steroid administration relieved severe refractory gastro-intestinal graft-vs.-host disease in an allogeneic bone marrow transplantation patient. Am J Hematol 1997; 56: 277-80.
290. Shapira MY, Bloom AI, Or R et al. Intra-arterial catheter directed therapy for severe graft-versushost disease. Br J Haematol 2002; 119: 760-4.
291. Bloom AI, Shapira MY, Or R et al. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. Clin Ther 2004; 26: 407-14.
292. Shapira MY, Resnick IB, Bitan M et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versushost disease: a preliminary report. Bone Marrow Transplant 2005; 36: 1097-101.
293. Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-8.
294. Bianco JA, Higano C, Singer J, Appelbaum FR, McDonald GB. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990; 49: 1194-5.
295. Ippoliti C, Champlin R, Bugazia N et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350-4.
296. Tanaka Y, Kami M, Ogawa S et al. Hyperacute graft-versus-host disease and NKT cells. Am J Hematol 2000; 63: 60-1.
297. Saliba RM, de Lima M, Giralt S et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109: 2751-8.
298. Kim DH, Sohn SK, Kim JG et al. Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 1025-30.
299. Davies SM, Weisdorf DJ, Haake RJ et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 73-7.
300. Sullivan KM, Deeg HJ, Sanders J et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67: 1172-5.
301. Hess AD. Autologous graft-versus-host disease. J Hematother Stem Cell Res 2000; 9: 297.
302. Santos GW. Autologous graft-versus-host disease. Leukemia. 1992;6 Suppl 4:110-111.
303. Miura Y, Thoburn CJ, Bright EC, Hess AD. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand. Biol Blood Marrow Transplant 2004; 10: 156-70.
304. Giralt S, Weber D, Colome M et al. Phase I trial of cyclosporine-induced autologous graft-versushost disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667-73.
305. Pati AR, Godder KT, Abhyankar SH, Gee AP, Henslee-Downey PJ. Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplant 1996; 17: 1081-3.
306. Yeager AM, Vogelsang GB, Jones RJ et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 1993; 11: 215-20.
307. Holmberg L, Kikuchi K, Gooley TA et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226-34.
308. Saunders MD, Shulman HM, Murakami CS et al. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004-8.
309. Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-5.
310. Zenz T, Ritgen M, Dreger P et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 108: 2127-30.
311. Greenbaum BH. Transfusion-associated graftversus- host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991; 9: 1889-902.
312. Parkman R, Mosier D, Umansky I et al. Graftversus- host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 1974; 290: 359-63.
313. Weiden PL, Zuckerman N, Hansen JA et al. Fatal graft-versus-host disease in a patient with lymphoblastic leukemia following normal granulocyte transfusion. Blood 1981; 57: 328-32.
314. Greenbaum BH. Transfusion-associated graftversus- host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991; 9: 1889-902.
315. Schroeder ML. Transfusion-associated graftversus- host disease. Br J Haematol 2002; 117: 275-87.
316. Nishimura M, Uchida S, Mitsunaga S et al. Identification of HLA class II antigens as the targets of effector clones which may cause transfusionassociated graft-versus-host disease. Transfus Med 1997; 7: 89-94.
317. Nishimura M, Uchida S, Mitsunaga S et al. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Blood 1997; 89: 1440-45.
318. Schroeder ML. Transfusion-associated graftversus- host disease. Br J Haematol 2002; 117: 275-87.
319. Juji T, Takahashi K, Shibata Y et al. Posttransfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989; 321: 56.
320. Capon SM, DePond WD, Tyan DB et al. Transfusion- associated graft-versus-host disease in an immunocompetent patient. Ann Intern Med 1991; 114: 1025-6.
321. Kruskall M, Alpher C, Awdeh Z. HLAhomozygous donors and transfusion-associated graft-versus-host disease. N Engl J Med 1990; 322: 1004-7.
322. Shivdasani RA, Haluska FG, Dock NL et al. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993; 328: 766-70.
323. Juji T, Takahashi K, Shibata Y et al. Posttransfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989; 321: 56.
324. Thomas ED, Herman EC, Jr., Greenough WB, III et al. Irradiation and marrow infusion in leukemia. Observations in five patients with acute leukemia treated by whole-body exposures of 1,400 to 2,000 roentgens and infusions of marrow. Arch Intern Med 1961; 107: 829-45.
325. Button LN, DeWolf WC, Newburger PE, Jacobson MS, Kevy SV. The effects of irradiation on blood components. Transfusion 1981; 21: 419-26.
326. Anderson KC, Goodnough LT, Sayers M et al. Variation in blood component irradiation practice: implications for prevention of transfusionassociated graft-versus-host disease. Blood 1991; 77: 2096-102.
327. Drobyski W, Thibodeau S, Truitt RL et al. Thirdparty- mediated graft rejection and graft-versushost disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989; 74: 2285-94.
328. Moroff G, Luban NL. The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev 1997; 11: 15-26.
329. AABB Technical Manual. 15 ed. AABB; 2005.
330. Standards for Blood Banks and Transfusion Services. 24 ed. AABB; 2006.
331. Pelszynski MM, Moroff G, Luban NL, Taylor BJ, Quinones RR. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683-9.
332. Schroeder ML. Transfusion-associated graftversus- host disease. Br J Haematol 2002; 117: 275-87.
333. Grass JA, Wafa T, Reames A et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-7.
334. Akahoshi M, Takanashi M, Masuda M et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169-72.
335. Hayashi H, Nishiuchi T, Tamura H, Takeda K. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993; 79: 1419-21.
336. Prince M, Szer J, van der Weyden MB et al. Transfusion associated graft-versus-host disease after cardiac surgery: response to antithymocyteglobulin and corticosteroid therapy. Aust N Z J Med 1991; 21: 43-6.
337. Cohen D, Weinstein H, Mihm M, Yankee R. Nonfatal graft-versus-host disease occurring after transfusion with leukocytes and platelets obtained from normal donors. Blood 1979; 53: 1053-7.